Your browser doesn't support javascript.
loading
Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.
Sempio, Cristina; Huestis, Marilyn A; Mikulich-Gilbertson, Susan K; Klawitter, Jost; Christians, Uwe; Henthorn, Thomas K.
Afiliação
  • Sempio C; Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Huestis MA; The Lambert Center for the Study of Medicinal Cannabis and Hemp, The Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Mikulich-Gilbertson SK; Department of Psychiatry, Division of Substance Dependence, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Klawitter J; Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, Colorado, USA.
  • Christians U; Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Henthorn TK; Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Br J Clin Pharmacol ; 86(3): 611-619, 2020 03.
Article em En | MEDLINE | ID: mdl-31747464
ABSTRACT

AIMS:

Population pharmacokinetic models of Δ9-tetrahydrocannabinol (THC) have been developed for THC plasma and blood concentration data. Often, only the metabolites of THC are measurable when blood samples are obtained. Therefore, we performed a population pharmacokinetic analysis of THC, 11-OH-THC and THCCOOH plasma concentration data from a Phase I clinical trial of THC smoking.

METHODS:

Frequently obtained plasma THC, 11-OH-THC and THCCOOH concentration data were obtained over 168 h from 6 subjects who smoked low (15.8 mg) and high dose (33.8 mg) THC cigarettes on 2 occasions. Bayesian estimates of the THC pharmacokinetic model from each individual for each dose were fixed prior to the sequential pharmacokinetic analysis of the metabolites.

RESULTS:

A 3-compartment model of THC was developed that has a steady-state volume of distribution (VdSS ) of 3401 ± 788 L and a clearance of 0.72 ± 0.10 L/min. 11-OH-THC was characterized by 50 ± 6% of the THC being directly cleared to a 3-compartment model with a VdSS of 415.2 ± 4.3 L and clearance of 0.78 ± 0.05 L/min. The THCCOOH model shared the central compartment of the 11-OH-THC model with a VdSS of 29.1 ± 0.05 L and a clearance of 0.12 ± 0.02 L/min. First order kinetics were observed for THC and THCCOOH between the low and high doses, but a nonlinear pattern was observed for 11-OH-THC.

CONCLUSION:

We describe the pharmacokinetics of THC, 11-OH-THC and THCCOOH including inter- and intraindividual variability of the parameter estimates of the model.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cannabis / Fumar Maconha Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cannabis / Fumar Maconha Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article